Dr. Ana B. Oton is Vice-president of Medical Affairs for the nirogacestat program at SpringWorks Therapeutics, a clinical-stage company focused in developing new targeted treatment options for patients with oncologic diseases. She obtained her medical degree at the Universidad Central of Venezuela in Caracas. She completed her Internal Medicine Residency at Jackson Memorial Hospital in Miami and her fellowship in Hematology/Oncology at the University of Pittsburgh. Dr. Oton was Associate Professor in Oncology at Denver Health (DH) Center with a dual appointment at the University of Colorado. She was also the Chair of the Cancer Committee and Director of the Clinical Trials Program at DH prior transitioning to Pharmaceutical Industry. Dr. Oton joined Eli Lilly in 2014 where she led the US and Global Medical Affairs Thoracic Oncology strategy for 4 years and led the lifecycle development program of Lilly’s CDK4/6 inhibitor for 2 years.